Periodic Reporting for period 4 - MCTRinIA (Resolution Pharmacology and Physiology of MCTR in Arthritis)
Okres sprawozdawczy: 2020-09-01 do 2021-08-31
The findings made during this grant demonstrate that MCTRs carry potent anti-inflammatory and tissue regenerative activities in experimental joint inflammation reducing both clinical signs of arthritis and promoting the repair or damaged tissues. These findings are significant since we also found that in patients with rheumatoid arthritis (RA) MCTR levels are reduced i with increasing with disease severity. Therefore these results suggest that MCTRs may be useful novel diagnostics and therapeutics in the management and treatment of patients with RA.
These findings support a central role of MCTRs in regulating both inflammation and mechanisms central to the repair and regeneration of damaged joints in the context of rheumatoid arthritis and potentially other chronic inflammatory conditions characterised by persistent chronic inflammation. Given the potential implications of these findings in both patient management and treatment we are presently engaged in both identifying exploitation routes for these findings. As part of these efforts we have established a Spin Out company (Resolomics Ltd) that aims to develop diagnostics for patient stratification. We are also furthering the development of cell-based therapeutics for the treatment of patients with RA. As part of the dissemination efforts, in addition to publishing our work in highlight visible high quality journals and presenting our work at a range of national and international meetings, we have engaged with several online platforms to disseminate the findings from our studies to the general public, these included The Conversation and Health Europa.